Compare GNPX & CTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNPX | CTNT |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 4.7M |
| IPO Year | 2017 | 2023 |
| Metric | GNPX | CTNT |
|---|---|---|
| Price | $4.70 | $1.81 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 109.2K | ★ 364.6K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,288,536.00 |
| Revenue This Year | N/A | $42.49 |
| Revenue Next Year | N/A | $22.22 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 182.69 |
| 52 Week Low | $0.14 | $0.02 |
| 52 Week High | $12.97 | $4.21 |
| Indicator | GNPX | CTNT |
|---|---|---|
| Relative Strength Index (RSI) | 53.44 | 54.87 |
| Support Level | $1.06 | $1.47 |
| Resistance Level | $9.99 | $1.95 |
| Average True Range (ATR) | 0.87 | 0.16 |
| MACD | -0.19 | 0.03 |
| Stochastic Oscillator | 48.69 | 70.91 |
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Cheetah Net Supply Chain Service Inc is a provider of logistics and warehousing services, historically in connection with the sale of parallel-import vehicles sourced in the U.S. to be sold in the PRC market, and more recently for the transportation of other goods between the U.S. and the PRC. Parallel-import vehicles in the PRC refer to automobiles purchased directly from overseas markets and imported for sale outside of the brand manufacturer's official distribution networks. The company operates as single report segment. The company operates in the USA and overseas.